Résultats de la recherche - 8 results
Expert report on FLAKKA
psychoactive substances (research chemicals) Nieuwe psychoactieve substanties (designer drugs) Nouvelles substances psychoactives Manuscript versions: DOI: https://sciensano.be/en/10.25608/2cjv-5v05 File: ...
Monitoring HIV pre-exposure prophylaxis programmes in the EU/EEA
intended to be used by PrEP programme implementers (e.g. public health authorities, non-governmental and community organisations or researchers) or other stakeholders in the design and implementation of ...
Opinion on Synthetic Biology II- Risk assessment methodologies and safety aspects
1831-4783; ISBN 978-92-79-43916-2 Keywords: a additional an Animal application Area Areas AS assessment at Biology Canada Combination Countries criteria definition Design Development Engineering environment ...
Opinion on Synthetic Biology- I. Definition
1831-4783; ISBN 978-92-79-30136-0 Keywords: a additional an application Area Areas AS aspects assessment at Biology Canada Combination concept concepts Countries criteria definition Design Development ...
The consistency approach for quality control of vaccines- a strategy to improve quality control and implement 3Rs
Control recommendation Recommendations report Research Design routine SB- IM STANDARD standards Strategies Strategy System Test TESTING tests The Netherlands use vaccine vaccines veterinary Veterinary ...
General report of Scanner
like Scanner) Summary of the SCANNER project results Lessons learned Health Topics: New psychoactive substances (research chemicals) Nieuwe psychoactieve substanties (designer drugs) Nouvelles substances ...
Evaluation of the Cancer Plan 2008-2010: Results 2011
patients, and research, innovation and evaluations in which individual initiatives are presented. The design of the evaluation of the Cancer Plan 2008-2010 was carried out in six consecutive phases, each ...
IPAAC Rapport WP4: Cancer control policy interview survey
design’ is crucial and requires global strategies and resources. In a context of increasing prevalence the lack of data on the whole disease trajectory, including quality of life and survivorship, is ...